

WHAT IS CLAIMED IS:

Sub
AL 1. A method for the formulation and delivery of an acid-labile pharmaceutical compound from among at least the group of substituted benzimidazoles and pancreatic enzyme supplements, said method comprising:

- 5 a. providing an active pharmaceutical compound;
- b. providing a basic salt as one of a suspension and a solution;
- 10 c. combining said pharmaceutical compound in a form as one of a tablet, a capsule, a powder, a solution and a suspension to provide said acid-labile pharmaceutical compound.

2. A method for the formulation and delivery of an acid-labile pharmaceutical compound from among at least the group of substituted benzimidazoles and pancreatic enzyme supplements as claimed in Claim 1, wherein said one of said basic salt solution and suspension has a pH greater than 7.0.

506
A2 3. A method for the formulation and delivery of an acid-labile pharmaceutical compound from among at least the group of substituted benzimidazoles and pancreatic enzyme supplements as claimed in Claim 2, wherein said
5 basic salt is one of a Type IA and Type II metal salt.

Group?

4. A method for the formulation and delivery of an acid-labile pharmaceutical compound from among at least the group of substituted benzimidazoles and pancreatic enzyme supplements as claimed in Claim 3, wherein said
5 metal salt is one of sodium, potassium, magnesium, calcium and aluminum salt.

5. A method for the formulation and delivery of an acid-labile pharmaceutical compound from among at least the group of substituted benzimidazoles and pancreatic enzyme supplements as claimed in Claim 1, wherein said
5 compound in said formulation includes a therapeutic dose of said pharmaceutical compound.

112
doesn't
recite to do
who!

6. A method for the formulation and delivery of an acid-labile pharmaceutical compound as claimed in Claim 1, further providing an enteric-coated formulation for said pharmaceutical compound formulation; and,
5 combining said enteric-coated formulation by one of mixing, dissolving and suspending with said one of

said basic ~~salt~~, basic salt solution and basic salt suspension to provide said acid-labile pharmaceutical compound.

1. 0.1% solution

sub
A3 7. An acid-labile pharmaceutical compound having at least substituted benzimidazoles and pancreatic enzyme supplements, said acid-labile pharmaceutical compound comprising:

5 a. an active pharmaceutical compound;

b. a basic salt, which basic salt is at least one of a solution and suspension;

c. said one of said solution and suspension having a pH greater than 7.0;

10 d. said active pharmaceutical compound and said basic salt combined as at least one of a form of a tablet, capsule, and powder; and

e. said at least one of a form of a tablet, capsule and powder provided to said one of a solution and
15 suspension to provide said acid-labile pharmaceutical compound operable to provide at least one of neutralization of gastric acid and temporary stimulation of gastric acid secretion.

8. An acid-labile pharmaceutical compound as claimed in Claim 7, wherein said basic salt is one of a Type I and Type IIA metal.

9. An acid-labile pharmaceutical compound as claimed in Claim 8, wherein said metal is one of sodium, potassium, magnesium, calcium and aluminum.

10. An acid-labile pharmaceutical compound as claimed in Claim 7, wherein said pharmaceutical compound in said at least one form has at least a therapeutic dose of said pharmaceutical compound.

11. An acid-labile pharmaceutical compound as claimed in Claim 10, wherein said at least one form of said pharmaceutical compound has said basic salt in each said therapeutic dose, said basic salt having a
5 concentration between about 1mM and about 1M per therapeutic dose.

12. An acid-labile pharmaceutical compound as claimed in Claim 7, wherein said compound may be dispensed in said form of a tablet, capsule, powder, solution and suspension.

510
AP 13. An acid-labile pharmaceutical compound as
claimed in Claim 7, wherein said compound may be
administered into a gastrointestinal tract by at least
one of orally and by artificial tube, said tube being at
5 least one of nasogastric tube, nasoduodenal tube,
hasojejunal tube, orogastric tube, oraduodenal tube
orajejunal tube, gastrotomy tube and jejunostomy tube.

14. An acid-labile pharmaceutical compound as
claimed in Claim 13, wherein said gastrotomy tube and
jejunostomy tube may be provided by at least one of
surgical, radiological and endoscopical means.

15. An acid-labile pharmaceutical compound as
claimed in Claim 13, wherein said compound is provided
and mixed in one of ~~the~~ said solution and suspension for
introduction to a patient through said tube.

16. A method for the formulation and delivery of
an acid-labile pharmaceutical compound as claimed in
Claim 1, wherein said benzimidazole compound is one of
omeprazole, lansoprazole, pantoprazole, rabeprazole and
5 esomeprazole.